Bidirectional associations between psoriasis and migraine: A systematic review and meta‐analysis

Abstract

SummaryBackground and ObjectivesTo evaluate the association between psoriasis and migraine.Patients and MethodsMEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched for relevant observational studies from their respective inception to May 1, 2022. A random‐effects model meta‐analysis was performed to calculate the risk estimates quantifying the associations between psoriasis and migraine. We also performed a sensitivity analysis by including only studies with adjusted risk estimates and a subgroup analysis according to the severity of psoriasis.ResultsWe included 9 studies with 6,742,075 participants. The meta‐analysis illustrated increased odds for prevalent migraine among patients with psoriasis (pooled OR: 1.69, 95% CI: 1.26–2.28) and increased odds for prevalent psoriasis among those with migraine (OR: 1.88, 95% CI: 1.32–3.67). A subgroup analysis of cohort studies demonstrated an increasingly higher risk of incident migraine in patients with mild psoriasis and severe psoriasis (IRR being 1.37 (95% CI 1.30–1.44) and 1.55 (95% CI 1.29–1.86), respectively).ConclusionsThis meta‐analysis revealed significant bidirectional associations between migraine and psoriasis. Greater severity of psoriasis appears to be associated with a higher risk of developing migraine. Clinicians should evaluate symptoms of migraine in patients with psoriasis and provide proper treatments.